KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to 0.57%.

  • Halozyme Therapeutics' Return on Capital Employed rose 3200.0% to 0.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.57%, marking a year-over-year increase of 3200.0%. This contributed to the annual value of 0.31% for FY2024, which is 1100.0% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Return on Capital Employed of 0.57% as of Q3 2025, which was up 3200.0% from 0.34% recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Return on Capital Employed peaked at 0.57% during Q3 2025, and registered a low of 0.15% during Q3 2022.
  • In the last 5 years, Halozyme Therapeutics' Return on Capital Employed had a median value of 0.25% in 2024 and averaged 0.26%.
  • The largest annual percentage gain for Halozyme Therapeutics' Return on Capital Employed in the last 5 years was 4500bps (2021), contrasted with its biggest fall of -8400bps (2021).
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Return on Capital Employed stood at 0.27% in 2021, then crashed by -42bps to 0.16% in 2022, then increased by 28bps to 0.2% in 2023, then soared by 42bps to 0.28% in 2024, then skyrocketed by 101bps to 0.57% in 2025.
  • Its last three reported values are 0.57% in Q3 2025, 0.34% for Q2 2025, and 0.3% during Q1 2025.